Under the collaboration, the companies will develop tests, which will be based on Qiagen’s Modaplex analysis platform. Qiagen claims that the multi-modal, multi-analyte Modaplex analysis platform can process multiple sample types and biomarkers in a single test.
Qiagen CEO Peer M Schatz said that the company is excited to add a new stage to its successful collaboration with Lilly, this time co-developing a broad panel of molecular assays covering a range of biomarkers with diverse nucleic acid analytes and modalities to guide the use of tailored therapies.
"Our collaborations with Lilly are among more than 20 co-development and co-commercialization projects underway with leading pharmaceutical and biotechnology companies," Schatz added.
The new collaboration is the fourth project in the two companies’ long-standing partnership.
Image: Eli Lilly and Company’s global headquarters, in Indianapolis, US. Photo: Courtesy of Guanaco152003
